Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2779 - Effect of baseline metabolic aberrations in men with locally advanced/metastatic prostate cancer treated with ADT on time to disease progression, prostate cancer specific and all cause death


09 Oct 2016


Poster display


Danielle Crawley


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


D. Crawley1, M. van Hemelrijck1, S. Chowdhury2, N. James3, C. Gilson4, M. Spears4, M.R. Sydes4, S. Rudman2

Author affiliations

  • 1 Research Oncology, King's College London Guy's Hospital, SE1 9RT - London/GB
  • 2 Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 3 Clinical Trial Unit, University of Warwick, CV4 7AL - Coventry/GB
  • 4 Clinical Trials Unit, Medical Research Council (MRC) MRC Clinical Trials Unit, WC2B 6NH - London/GB


Abstract 2779


Metabolic conditions (diabetes, obesity, or dyslipidaemia) may be linked with prostate cancer (PCa) aggressiveness and death. The presence of these metabolic aberrations may enable us to identify those men who are at risk of early treatment failure. Here, we examine the effect of baseline metabolic aberrations on time to disease progression, PCa specific and all cause death in a cohort of men with locally advanced/metastatic PCa treated with long term androgen deprivation therapy (ADT).


This study was conducted using a retrospective review of case report forms (CRF) of 2,617 men with locally advanced/metastatic hormone naïve PCa commencing long term ADT who enrolled in the control arm of the STAMPEDE trial (ISRCTN78818544) between 2005 and 2015. Data on the following metabolic aberrations at baseline was included: hypertension (systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg or confirmed history of hypertension), obesity (BMI >30kg/m2),dyslipidaemia (HDL


During a median follow up of 1.75 years those with three or more metabolic aberrations at baseline were more likely to have local progression (HR: 1.61, 95% CI: 1.09-2.36) after adjusting for age, Gleason score, PSA, type of ADT and TNM stage. A similar trend was seen for metastatic progression (HR: 1.24, 95% CI: 0.97-1.58).


Our findings suggest that baseline metabolic aberrations may be associated with earlier treatment failure. Thus identifying a higher risk patient group in which to intensify therapy including management of metabolic risk. Further prospective studies examining this association are required.

Clinical trial identification

EudraCT 2004-000193-31 ISRCTN78818544

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings